A Jennifer Morton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7267582/publications.pdf

Version: 2024-02-01

139 papers	8,461 citations	41323 49 h-index	49868 87 g-index
145 all docs	145 docs citations	145 times ranked	7578 citing authors

#	Article	IF	Citations
1	Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntingtonâ€™s Disease Mutation. Journal of Neuroscience, 1999, 19, 3248-3257.	1.7	864
2	Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation. Journal of Neuroscience, 2000, 20, 5115-5123.	1.7	366
3	Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease. Journal of Neuroscience, 2005, 25, 157-163.	1.7	361
4	Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation. Journal of Neuroscience, 1999, 19, 10428-10437.	1.7	355
5	Choosing an animal model for the study of Huntington's disease. Nature Reviews Neuroscience, 2013, 14, 708-721.	4.9	287
6	Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiology of Disease, 2009, 35, 319-336.	2.1	281
7	The touchscreen cognitive testing method for rodents: How to get the best out of your rat. Learning and Memory, 2008, 15, 516-523.	0.5	228
8	Pharmacological Imposition of Sleep Slows Cognitive Decline and Reverses Dysregulation of Circadian Gene Expression in a Transgenic Mouse Model of Huntington's Disease. Journal of Neuroscience, 2007, 27, 7869-7878.	1.7	185
9	Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. European Journal of Neuroscience, 2004, 20, 3092-3114.	1.2	151
10	Solving the shepherding problem: heuristics for herding autonomous, interacting agents. Journal of the Royal Society Interface, 2014, 11, 20140719.	1.5	140
11	Abnormalities in the synaptic vesicle fusion machinery in Huntingtonâ€™s disease. Brain Research Bulletin, 2001, 56, 111-117.	1.4	127
12	Disruption of Peripheral Circadian Timekeeping in a Mouse Model of Huntington's Disease and Its Restoration by Temporally Scheduled Feeding. Journal of Neuroscience, 2010, 30, 10199-10204.	1.7	125
13	Abnormalities of Neurogenesis in the R6/2 Mouse Model of Huntington's Disease Are Attributable to the In Vivo Microenvironment. Journal of Neuroscience, 2005, 25, 11564-11576.	1.7	116
14	Ecstasy: pharmacology and neurotoxicity. Current Opinion in Pharmacology, 2005, 5, 79-86.	1.7	116
15	Circadian and sleep disorder in Huntington's disease. Experimental Neurology, 2013, 243, 34-44.	2.0	115
16	Dopamine Modulates the Susceptibility of Striatal Neurons to 3-Nitropropionic Acid in the Rat Model of Huntingtonâ€™s Disease. Journal of Neuroscience, 1998, 18, 10116-10127.	1.7	114
17	Increased metabolism in the R6/2 mouse model of Huntingtonâ€™s disease. Neurobiology of Disease, 2008, 29, 41-51.	2.1	114
18	Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiology of Disease, 2009, 33, 331-341.	2.1	114

#	Article	IF	Citations
19	Selfish-herd behaviour of sheep under threat. Current Biology, 2012, 22, R561-R562.	1.8	114
20	Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs Candidate Gene Selection for Sporadic Parkinson Disease. American Journal of Human Genetics, 2018, 102, 427-446.	2.6	102
21	Complexin II is essential for normal neurological function in mice. Human Molecular Genetics, 2003, 12, 2431-2448.	1.4	101
22	The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study. Experimental Neurology, 2008, 210, 691-698.	2.0	99
23	The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2002, 81, 46-59.	2.1	98
24	Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Movement Disorders, 2000, 15, 925-937.	2.2	96
25	Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntingtonâ€™s Disease. Current Neurology and Neuroscience Reports, 2011, 11, 211-217.	2.0	93
26	Large Genetic Animal Models of Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 3-19.	0.9	92
27	Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2008, 76, 166-172.	2.1	85
28	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Research Bulletin, 2008, 76, 70-79.	1.4	82
29	Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease. Brain Research, 2009, 1279, 90-98.	1.1	81
30	Measuring cognitive deficits in disabled mice using an automated interactive touchscreen system. Nature Methods, 2006, 3, 767-767.	9.0	78
31	Early and progressive circadian abnormalities in Huntington's disease sheep are unmasked by social environment. Human Molecular Genetics, 2014, 23, 3375-3383.	1.4	78
32	Metabolic profiling of presymptomatic Huntingtonâ€™s disease sheep reveals novel biomarkers. Scientific Reports, 2017, 7, 43030.	1.6	78
33	Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. Human Gene Therapy, 2018, 29, 663-673.	1.4	74
34	Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntingtonâ€™s disease mutation. Brain Research Bulletin, 2003, 61, 375-383.	1.4	73
35	Responses to Environmental Enrichment Differ with Sex and Genotype in a Transgenic Mouse Model of Huntington's Disease. PLoS ONE, 2010, 5, e9077.	1.1	73
36	A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. European Journal of Neuroscience, 2005, 21, 855-870.	1.2	71

#	Article	IF	Citations
37	Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits. Human Molecular Genetics, 2005, 14, 2369-2385.	1.4	71
38	â€œBrain trainingâ€•improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 2011, 42, 427-437.	2.1	70
39	Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. Journal of Cell Science, 2008, 121, 3901-3911.	1.2	63
40	Progressive sleep and electroencephalogram changes in mice carrying the Huntingtonâ€™s disease mutation. Brain, 2013, 136, 2147-2158.	3.7	63
41	Olfactory abnormalities in Huntingtonâ€™s disease: Decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Research, 2007, 1151, 219-226.	1.1	62
42	Voxel-based morphometry with templates and validation in a mouse model of Huntingtonâ€™s disease. Magnetic Resonance Imaging, 2013, 31, 1522-1531.	1.0	62
43	Mice transgenic for the human Huntingtonâ€™s disease mutation have reduced sensitivity to kainic acid toxicity. Brain Research Bulletin, 2000, 52, 51-59.	1.4	61
44	Executive Decision-Making in the Domestic Sheep. PLoS ONE, 2011, 6, e15752.	1.1	59
45	Microglia density decreases with age in a mouse model of Huntington's disease. Glia, 2003, 43, 274-280.	2.5	57
46	The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: Influence of non-motor factors on locomotor function. Brain Research Bulletin, 2009, 78, 347-355.	1.4	56
47	Sheep recognize familiar and unfamiliar human faces from two-dimensional images. Royal Society Open Science, 2017, 4, 171228.	1.1	56
48	Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntingtonâ€™s disease is not improved by treatment with hypoglycaemic agents. Experimental Brain Research, 2005, 166, 220-229.	0.7	54
49	Determining association networks in social animals: choosing spatialâ€“temporal criteria and sampling rates. Behavioral Ecology and Sociobiology, 2011, 65, 1659-1668.	0.6	54
50	Combining Comparative Proteomics and Molecular Genetics Uncovers Regulators of Synaptic and Axonal Stability and Degeneration In Vivo. PLoS Genetics, 2012, 8, e1002936.	1.5	54
51	A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexinâ€ƒII knockout mouse. European Journal of Neuroscience, 2005, 22, 1701-1712.	1.2	52
52	Mice Transgenic for the Huntington's Disease Mutation Are Resistant to Chronic 3-Nitropropionic Acid-Induced Striatal Toxicity. Journal of Neurochemistry, 2002, 75, 2163-2171.	2.1	50
53	mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntingtonâ€™s Disease. Molecular Cell, 2018, 71, 675-688.e6.	4.5	50
54	RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxicâ€“ischemic brain injury in rats. Brain Research, 2003, 966, 167-174.	1.1	49

#	Article	IF	Citations
55	Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal. Human Molecular Genetics, 2007, 16, 2288-2305.	1.4	49
56	Expression of Mutant Huntingtin Blocks Exocytosis in PC12 Cells by Depletion of Complexin II. Journal of Biological Chemistry, 2003, 278, 30849-30853.	1.6	48
57	Further Molecular Characterisation of the OVT73 Transgenic Sheep Model of Huntington's Disease Identifies Cortical Aggregates. Journal of Huntington's Disease, 2013, 2, 279-295.	0.9	47
58	Expression levels of DNA replication and repair genes predict regional somatic repeat instability in the brain but are not altered by polyglutamine disease protein expression or age. Human Molecular Genetics, 2014, 23, 1606-1618.	1.4	47
59	Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease. Neurobiology of Disease, 2011, 42, 438-445.	2.1	45
60	Progressive imbalance in the interaction between spatial and procedural memory systems in the R6/2 mouse model of Huntingtonâ€™s disease. Neurobiology of Learning and Memory, 2009, 92, 417-428.	1.0	44
61	Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 2014, 63, 85-91.	2.1	41
62	Binding sites for125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells. Brain Research, 1991, 554, 278-285.	1.1	40
63	Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntingtonâ€™s Disease mutation. Brain Research Bulletin, 2004, 63, 45-55.	1.4	39
64	Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Research Bulletin, 2008, 75, 146-157.	1.4	39
65	Translational neurophysiology in sheep: measuring sleep and neurological dysfunction in CLN5 Batten disease affected sheep. Brain, 2015, 138, 862-874.	3.7	39
66	Accelerated Differentiation in Response to Retinoic Acid After Retrovirally Mediated Gene Transfer of GAP-43 into Mouse Neuroblastoma Cells. European Journal of Neuroscience, 1992, 4, 910-916.	1.2	36
67	Rigidity in social and emotional memory in the R6/2 mouse model of Huntingtonâ€™s disease. Neurobiology of Learning and Memory, 2008, 89, 533-544.	1.0	36
68	Beneficial effects of environmental enrichment and food entrainment in the R6/2 mouse model of <scp>H</scp>untington's disease. Brain and Behavior, 2014, 4, 675-686.	1.0	36
69	Identifying sleep disturbances in Huntingtonâ€™s disease using a simple disease-focused questionnaire. PLOS Currents, 2010, 2, RRN1189.	1.4	36
70	Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b. Brain Research, 1992, 581, 299-306.	1.1	35
71	Methamphetamine toxicity in mice is potentiated by exposure to loud music. NeuroReport, 2001, 12, 3277-3281.	0.6	34
72	Age-, tissue- and length-dependent bidirectional somatic CAGâ€¢CTG repeat instability in an allelic series of R6/2 Huntington disease mice. Neurobiology of Disease, 2015, 76, 98-111.	2.1	33

#	Article	IF	Citations
73	Early motor development is abnormal in complexin 1 knockout mice. Neurobiology of Disease, 2007, 25, 483-495.	2.1	32
74	Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation. Brain Research, 2008, 1188, 61-68.	1.1	32
75	Direct Evidence of Progressive Cardiac Dysfunction in a Transgenic Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 57-64.	0.9	31
76	Differential messenger RNA expression of complexins in mouse brain. Brain Research Bulletin, 2004, 63, 33-44.	1.4	29
77	Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Neurobiology of Disease, 2007, 25, 342-353.	2.1	28
78	The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 2012, 45, 145-155.	2.1	28
79	An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep. Journal of Neuroscience, 2016, 36, 8238-8249.	1.7	27
80	A mobile, high-throughput semi-automated system for testing cognition in large non-primate animal models of Huntington disease. Journal of Neuroscience Methods, 2016, 265, 25-33.	1.3	27
81	Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. Brain Research Bulletin, 2006, 69, 669-679.	1.4	26
82	Techniques for chronic monitoring of brain activity in freely moving sheep using wireless EEG recording. Journal of Neuroscience Methods, 2017, 279, 87-100.	1.3	26
83	Technical note: Validation of an automatic recording system to assess behavioural activity level in sheep (Ovis aries). Small Ruminant Research, 2015, 127, 92-96.	0.6	25
84	Temporal Separation of Aggregation and Ubiquitination during Early Inclusion Formation in Transgenic Mice Carrying the Huntingtonâ€™s Disease Mutation. PLoS ONE, 2012, 7, e41450.	1.1	22
85	Tensor-Based Morphometry and Stereology Reveal Brain Pathology in the Complexin1 Knockout Mouse. PLoS ONE, 2012, 7, e32636.	1.1	21
86	Abnormal patterns of sleep and EEG power distribution during non-rapid eye movement sleep in the sheep model of Huntington's disease. Neurobiology of Disease, 2021, 155, 105367.	2.1	21
87	Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging. PLoS ONE, 2015, 10, e0132331.	1.1	20
88	XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent. PLoS ONE, 2018, 13, e0194580.	1.1	20
89	Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD. Brain Research Bulletin, 2007, 72, 108-120.	1.4	19
90	Unusual Structures Are Present in DNA Fragments Containing Super-Long Huntingtin CAG Repeats. PLoS ONE, 2011, 6, e17119.	1.1	19

#	Article	IF	Citations
91	Progression of behavioural despair in R6/2 and Hdh knock-in mouse models recapitulates depression in Huntington's disease. Behavioural Brain Research, 2015, 291, 140-146.	1.2	19
92	Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. NeuroReport, 2006, 17, 1623-1627.	0.6	18
93	Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntingtonâ€™s disease. Histochemistry and Cell Biology, 2007, 127, 473-484.	0.8	18
94	A single dose of hypnotic corrects sleep and EEG abnormalities in symptomatic Huntington's disease mice. Neuropharmacology, 2016, 105, 298-307.	2.0	18
95	Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease?. Journal of Pineal Research, 2020, 68, e12624.	3.4	18
96	Large-Brained Animal Models of Huntingtonâ€™s Disease: Sheep. Methods in Molecular Biology, 2018, 1780, 221-239.	0.4	18
97	Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse. Human Molecular Genetics, 2010, 19, 3402-3412.	1.4	17
98	Right Ventricular Dysfunction in the R6/2 Transgenic Mouse Model of Huntington's Disease is Unmasked by Dobutamine. Journal of Huntington's Disease, 2014, 3, 25-32.	0.9	17
99	Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length Variation. Journal of Huntington's Disease, 2021, 10, 53-74.	0.9	16
100	Direct Visualisation of Abnormal Dendritic Spine Morphology in the Hippocampus of the R6/2 Transgenic Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 267-273.	0.9	15
101	Allelic series of Huntington's disease knock-in mice reveals expression discorrelates. Human Molecular Genetics, 2016, 25, 1619-1636.	1.4	15
102	A stop-signal task for sheep: introduction and validation of a direct measure for the stop-signal reaction time. Animal Cognition, 2017, 20, 615-626.	0.9	15
103	Prolonged day length exposure improves circadian deficits and survival in a transgenic mouse model of Huntington's disease. Neurobiology of Sleep and Circadian Rhythms, 2017, 2, 27-38.	1.4	15
104	Characteristic patterns of EEG oscillations in sheep (Ovis aries) induced by ketamine may explain the psychotropic effects seen in humans. Scientific Reports, 2020, 10, 9440.	1.6	15
105	Attenuated pupillary light responses and downregulation of opsin expression parallel decline in circadian disruption in two different mouse models of Huntingtonâ€™s disease. Human Molecular Genetics, 2016, 25, ddw359.	1.4	14
106	Potential molecular consequences of transgene integration: The R6/2 mouse example. Scientific Reports, 2017, 7, 41120.	1.6	14
107	Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2016, 5, 19-32.	0.9	13
108	Data-loggers carried on a harness do not adversely affect sheep locomotion. Research in Veterinary Science, 2012, 93, 549-552.	0.9	12

#	Article	IF	Citations
109	Social Behaviour is Impaired in the R6/2 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2015, 4, 61-73.	0.9	12
110	Indices of comparative cognition: assessing animal models of human brain function. Experimental Brain Research, 2018, 236, 3379-3390.	0.7	12
111	Abnormally abrupt transitions from sleep-to-wake in Huntingtonâ€™s disease sheep (Ovis aries) are revealed by automated analysis of sleep/wake transition dynamics. PLoS ONE, 2021, 16, e0251767.	1.1	11
112	Expression of calbindin D-28K-like immunoreactivity in human SK-N-SH and SH-SY-5Y neuroblastoma cells. Brain Research, 1990, 533, 161-164.	1.1	10
113	Restriction endonuclease TseI cleaves A:A and T:T mismatches in CAG and CTG repeats. Nucleic Acids Research, 2013, 41, 4999-5009.	6.5	10
114	Adaptation to Experimental Jet-Lag in R6/2 Mice despite Circadian Dysrhythmia. PLoS ONE, 2013, 8, e55036.	1.1	10
115	Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington's Disease Mice. Neurotherapeutics, 2017, 14, 1120-1133.	2.1	10
116	Characterisation of progressive motor deficits in whisker movements in R6/2, Q175 and Hdh knock-in mouse models of Huntingtonâ€™s disease. Journal of Neuroscience Methods, 2018, 300, 103-111.	1.3	9
117	Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntingtonâ€™s disease. Scientific Reports, 2019, 9, 37.	1.6	9
118	Recommendations for measuring whisker movements and locomotion in mice with sensory, motor and cognitive deficits. Journal of Neuroscience Methods, 2020, 331, 108532.	1.3	9
119	Huntingtonâ€™s Disease Mouse Models Online: High-Resolution MRI Images with Stereotaxic Templates for Computational Neuroanatomy. PLoS ONE, 2012, 7, e53361.	1.1	9
120	Characterizing Sleep Spindles in Sheep. ENeuro, 2020, 7, ENEURO.0410-19.2020.	0.9	9
121	Automated detection and characterisation of rumination in sheep using in vivo electrophysiology. Physiology and Behavior, 2016, 163, 258-266.	1.0	8
122	Progressive gene dose-dependent disruption of the methamphetamine-sensitive circadian oscillator-driven rhythms in a knock-in mouse model of Huntington's disease. Experimental Neurology, 2016, 286, 69-82.	2.0	8
123	Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease. Neuropharmacology, 2018, 131, 337-350.	2.0	8
124	Visual attention and cognitive performance in sheep. Applied Animal Behaviour Science, 2018, 206, 52-58.	0.8	8
125	Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington's Disease. Neurotherapeutics, 2020, 17, 1075-1086.	2.1	8
126	Abnormal Photic Entrainment to Phase-Delaying Stimuli in the R6/2 Mouse Model of Huntington's Disease, despite Retinal Responsiveness to Light. ENeuro, 2019, 6, ENEURO.0088-19.2019.	0.9	8

#	Article	IF	Citations
127	Cortical induction of c-fos by intrastriatal endothelin-1 is mediated via NMDA receptors. NeuroReport, 1996, 8, 211-216.	0.6	6
128	Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6/2 Mouse Model Of Huntingtonâ€™s Disease. Scientific Reports, 2016, 6, 25979.	1.6	6
129	A comparison of discrimination learning in touchscreen and 2-choice swim tank using an allelic series of Huntington's disease mice. Journal of Neuroscience Methods, 2016, 265, 56-71.	1.3	5
130	The Cambridge MRI database for animal models of Huntington disease. NeuroImage, 2016, 124, 1260-1262.	2.1	4
131	Deep brain electrophysiology in freely moving sheep. Current Biology, 2022, 32, 763-774.e4.	1.8	4
132	Magic Molecules, How Drugs WorkSusan Aldridge Cambridge University Press, Cambridge, 1998 (269) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	3
133	Longitudinal Magnetic Resonance Spectroscopy andÂDiffusion Tensor Imaging in Sheep (Ovis aries) With Quinolinic Acid Lesions of the Striatum: Time-Dependent Recovery of N-Acetylaspartate and Fractional Anisotropy. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1084-1092.	0.9	3
134	Neurological Examination of Sheep (Ovis aries) with Unilateral and Bilateral Quinolinic Acid Lesions of the Striatum Assessed by Magnetic Resonance Imaging. Journal of Neurology and Experimental Neuroscience, 2019, 05, .	0.2	3
135	A Significance Test for Inferring Affiliation Networks from Spatio-Temporal Data. PLoS ONE, 2015, 10, e0132417.	1.1	2
136	Early Neurodegeneration in R6/2 Mice Carrying the Huntingtonâ€™s Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan. Journal of Huntington's Disease, 2018, 7, 61-76.	0.9	2
137	Similar Progression of Morphological andÂMetabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy. Journal of Huntington's Disease, 2016, 5, 271-283.	0.9	1
138	Expression and Localization ofKcne2in the Vertebrate Retina. , 2020, 61, 33.		1
139	Synaptic Dysfunction in Huntingtonâ€™s Disease. , 2011, , 233-255.		0